Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 10 of 12
Feb 22, 2026The preclinical Alzheimer’s drug relies on Korsana’s proprietary platform technology that enables antibodies to traverse the blood-brain barrier. This advancement parallels approaches by Roche and AbbVie, reflecting a significant leap in the therapeutic landscape against Alzheimer's disease.
Dr. Priya Nandakumar
Feb 19, 2026Current GLP-1 based obesity therapies, while effective for weight loss, present challenges including muscle loss and adherence issues. Innovators in the biotech field are exploring novel solutions such as preserving muscle mass, developing oral administration methods, and combining therapies to improve patient outcomes and sustain treatment adherence.
Jonathan Blake
Feb 18, 2026Alzheimer’s disease remains one of the most challenging neurodegenerative conditions with urgent demand for effective treatments. Korsana’s innovative approach utilizes next-generation shuttling technology to bolster brain delivery of antibodies, potentially minimizing amyloid-related imaging abnormalities and improving therapeutic outcomes. This post delves into Korsana’s strategy, funding landscape, and implications for Alzheimer's treatment development.
Jonathan Blake
Feb 18, 2026In a major advancement for treating wet age-related macular degeneration (AMD), Ocular Therapeutix reported that their novel drug Axpaxli met the primary endpoint in Phase 3 trials, demonstrating superior vision maintenance compared to Regeneron's established therapy Eylea. This success paves the way for regulatory filing and could shift treatment paradigms for wet AMD patients worldwide.
Jonathan Blake
Feb 17, 2026Recent clinical results from Compass Pathways suggest that psilocybin-based medicines might soon gain regulatory approval for treating severe depression. These pioneering trials mark a hopeful step towards integrating psychedelic compounds into mainstream mental health care.
Dr. Alex Morgan
Feb 16, 2026Despite longstanding dominance in biotech innovation, the United States faces risks that could alter its pioneering status. This analysis explores the factors influencing this pivotal period in American innovation and the potential implications for the biotech sector.
Emily Carter
Feb 14, 2026After a slow uptake period, the partnership between Vertex and CRISPR Therapeutics for Casgevy gene therapy targeting sickle cell disease and beta thalassemia is poised for substantial growth. This reflects the increasing acceptance and accessibility of advanced gene therapies in rare disease management.
Jonathan Blake
Feb 13, 2026The Mayo Clinic Platform offers a revealing perspective on the limitations of de-identified electronic health records (EHR) data, suggesting that extensive de-identification processes may diminish the data's practical value for pharma and research entities. This insight underscores the ongoing tension between patient privacy and the imperative for actionable, high-quality data in drug development.
Daniel Cho
Feb 12, 2026BridgeBio Pharma's recent clinical trial achievement with infigratinib marks a meaningful advancement in the treatment of achondroplasia. The drug demonstrated significant improvements in growth rates and body composition in children, offering hope to patients with this genetic condition. Regulatory pathways are now anticipated to proceed toward FDA filing within the year.
Daniel Cho
Feb 11, 2026After an enthusiastic response to its initial data last year, Pelage is now prepared to fully disclose the scientific foundation behind its innovative hair loss candidate. This development marks a significant shift in the approach to hair loss treatments, emphasizing rigorous scientific validation over mere topical solutions.
Sophia Reynolds
Feb 5, 2026Veradermics is developing a novel oral formulation of minoxidil, historically a topical treatment for hair loss, leveraging technology intended to reduce systemic side effects. With pivotal trials underway, the company aims to establish an effective and safer alternative for alopecia sufferers, entering a competitive market with significant unmet needs.
Michael Torres
Feb 3, 2026As the pandemic winds down, BioNTech and Moderna's once parallel trajectories have diverged significantly. BioNTech’s diversified modality strategy contrasts with Moderna’s mRNA-centric pipeline, highlighting strategic shifts in how these companies leverage their COVID-19 windfalls to fuel future growth.
Dr. Alex MorganMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.